DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Elmiron (Pentosan Polysulfate) - Reviews, Ratings, Comments by Patients


Share your experience: submit a drug review

Below are Elmiron (Pentosan Polysulfate) reviews, ratings, comments submitted by patients and caregivers. Based on a total of 1 ratings/reviews, Elmiron has an overall score of 9. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst. This information is not vetted and should not be cosidered as clinical evidence.

Elmiron review by 45 year old female patient

Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
Treatment Info
Condition / reason:   Interstitial Cystitis
Dosage & duration:   100 mg taken 3 x/day for the period of 5 years
Other conditions:   Lyme disease, hypothyroid
Other drugs taken:   too many to name - Detrol LA, Zyrtec, etc...
Reported Results
Benefits:   relief of symptoms of Interstitial cystitis, including pain and frequency of urination
Side effects:   Initially - feeling of wooziness, nausea, tiredness. This wore off after 6-8 weeks.
Comments:   Relieved my symptoms of Interstitial Cystitis significantly after 1 year or so on the drug. Even within 3 months it greatly reduced the pain associated with the disease and decreased the number of times I had to use the bathroom from >40 per day to <20 per day. With continued use, I believe it helped reduce inflammation/mast cell production in my bladder, and along with dietary changes and treatment for infections to my bladder wall lining caused by Lyme disease related organisms, Elmiron allowed my bladder to heal to some degree, reducing my symptoms further and my incidence of urinating to <10 times per day on average.

Share your experience: submit a drug review

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017